newsfilter
← Latest News
GlobeNewswire·

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the Phase 1/2 INSPIRE DUCHENNE clinical trial, with 53 participants dosed as of August 4, 2026 - - Solid expects to meet with the FDA in late Q4 2026